PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, …
Over the last 12 months, insiders at PAVmed Inc. have bought $0 and sold $0 worth of PAVmed Inc. stock.
On average, over the past 5 years, insiders at PAVmed Inc. have bought $96,666 and sold $377,824 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 100,000 shares for transaction amount of $62,320 was made by Glennon Michael J (director) on 2022‑12‑07.
2022-12-07 | director | 100,000 0.1128% | $0.62 | $62,320 | -32.26% | |||
2022-12-06 | director | 88,000 0.1032% | $0.64 | $56,082 | -31.07% | |||
2022-12-05 | director | 62,000 0.0713% | $0.69 | $42,606 | -37.26% | |||
2021-03-18 | Chairman and CEO | 7,500 0.0102% | $4.31 | $32,324 | +16.12% | |||
2020-11-25 | Sale | 10 percent owner | 33,203 0.0686% | $1.96 | $65,048 | +158.16% | ||
2020-11-24 | Sale | 10 percent owner | 53,036 0.11% | $2.00 | $105,876 | +154.27% | ||
2020-11-19 | Sale | 10 percent owner | 75,211 0.1596% | $1.83 | $137,418 | +184.27% | ||
2020-11-18 | Sale | 10 percent owner | 24,789 0.0502% | $1.78 | $44,164 | +178.02% | ||
2020-05-29 | Sale | 10 percent owner | 131,082 0.2912% | $1.98 | $259,477 | +5.03% | ||
2020-05-28 | Sale | 10 percent owner | 69,839 0.162% | $2.06 | $143,666 | +5.56% | ||
2019-05-24 | President & CFO | 5,000 0.0184% | $1.09 | $5,429 | +1.87% | |||
2019-05-23 | Chairman and CEO | 30,000 0.1072% | $1.09 | $32,850 | -1.80% | |||
2018-08-28 | Chairman and CEO | 30,000 0.1084% | $1.18 | $35,400 | -12.20% | |||
2018-06-08 | Sale | 10 percent owner | 18,300 0.0967% | $1.04 | $19,032 | +10.49% | ||
2018-06-01 | Sale | 10 percent owner | 532,255 2.6899% | $0.97 | $516,287 | +12.76% | ||
2017-11-20 | Chairman and CEO | 950 0.0075% | $4.70 | $4,465 | -66.22% | |||
2017-11-17 | Chairman and CEO | 601 0.0045% | $4.37 | $2,626 | -65.14% | |||
2017-09-15 | Chairman and CEO | 2,600 0.0238% | $8.77 | $22,814 | -76.88% | |||
2017-09-13 | Chairman and CEO | 300 0.0022% | $6.88 | $2,065 | -76.78% | |||
2017-09-12 | Chairman and CEO | 100 0.0007% | $6.66 | $666 | -76.15% |
First Manhattan Co. | $909,500.00 | 4.51 | 425,000 | +112.5% | +$481,500.00 | <0.01 | |
The Vanguard Group | $643,158.00 | 3.19 | 300,541 | -0.68% | -$4,419.10 | <0.0001 | |
BlackRock | $160,312.00 | 0.79 | 74,912 | -0.01% | -$21.40 | <0.0001 | |
Geode Capital Management | $135,626.00 | 0.67 | 63,360 | +15.04% | +$17,728.13 | <0.0001 | |
Valeo Financial Advisors LLC | $39,089.00 | 0.22 | 21,129 | 0% | +$0 | <0.0001 |